Novel potent and selective dopamine D3R partial agonist

Novel potent dopamine D3R antagonist

Novel modulator of proprotein convertase subtilisin kexin like type 9 (PCSK9)

Novel PCSK9 mRNA translation inhibitor

Novel PCSK9 mRNA translation inhibitor

Novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Novel inhibitor of PD-I/PD-L1 interaction to be used as a negative immune checkpoint regulatory and antineoplastic agent

Novel potent PD-1/PD-L1 antagonist (IC50 of 16.17 nM), activating the antitumor immunity of T cells efficiently in PBMCs

Novel bifunctional inhibitor of PD-1/PD-L1 interactions, promoting dimerization, internalization, and degradation of PD-L1, suppressing tumor growth in vivo by activating antitumor immunity

Novel Potent Inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Novel inhibitor of PD-1/PD-L1 (IC 50 value of 56.58 nM), dose-dependently promoting HepG2 cell death in a co-culture model of HepG2/hPD-L1 and Jurkat T cells, effectively inhibiting tumor growth (TGI of 76.4% at 90 mg/kg) in an immune checkpoint humanized

Novel potent programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor (IC50 9.1 nM)

Selective D3 dopamine receptor agonist

Selective antagonist for human ETA receptors

Neuropeptide Y Y1 receptor antagonist

AMPA receptor antagonist

AMPA receptor antagonist

Novel, potent, and selective NR1/2B NMDA receptor antagonist

Novel cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors

Novel selective inhibitor of STAT3 phosphorylation, binding to the SH2 domain of STAT3, exhibiting remarkable antiproliferative activity against three cancer cell lines (HCT-116, SW480 and MDA-MB-231)

Novel inducer of mitotic arrest and apoptosis in human progenitor and cancer cells

Novel G6PD inhibitor

Potent and selective second-generation phosphodiesterase type 5 (PDE5) inhibitor

Novel cell-permeable PDE7 inhibitor, targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element binding protein (CREB) pathway, exerting neuroprotection in an Alzheimer's disease (AD) model

Novel selective PDE9 inhibitor with strong antioxidant activity, inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease

Novel Potent, Selective, and Orally Bioavailable Inhibitor against Phosphodiesterase-9 (PDE9)

Novel inhibitor of melanogenesis

Novel Peptide Deformylase (PDF) Inhibitor

Protein disulfide isomerase (PDI) inhibitor

Novel PD-L1 degrader, showing 66.99% degradation activity at 20 μM with no calcium blocking effect, strengthening the T cell-mediated killing of tumor cells

Novel PROTAC dual inhibitor and degrader of PD-L1, inhibiting PD-1/PD-L1 interaction with IC50 of 39.2 nM in an HTRF binding assay

Novel Potent PD-L1 Inhibitor (IC50 1.8 nM), binding to human PD-L1 (hPD-L1) with a KD value of 3.34 nM, without showing any binding to hPD-1, blocking PD-1/PD-L1 interaction with an EC50 value of 375 nM

Novel pendrin inhibitor, inhibiting Cl-/anion exchange mediated by mouse pendrin without affecting other major kidney tubule transporters

Novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of acute myeloid leukemia (AML)

Activator of SHIP-1

Cyclooxygenase Inhibitor and Prostagladin Synthase Inhibitor

Novel caged glutamate

Antineoplastic agent, alkylating and crosslinking DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis

Mycotoxin with antibiotic and carcinogenic activity

Antibiotic, a natural penicillin, synthesized in vitro by incubating (S-octanoyl)glutathione, 6-APA and AT

Novel potent and broad-spectrum anti-influenza A virus (anti-IAV) activities with low risk of inducing drug resistance

Inhibitor of calcium-dependent complex formation with p53 [(Ca)S100B-p53] in malignant melanoma (MM), restoring p53 tumor suppressor activity in vivo

Innate defense regulator, target stringent response-controlled virulence in a Pseudomonas aeruginosa murine cutaneous infection model

ApoA-I/HDL mimetic peptide, efficiently crossing the blood-brain barrier and modulating amyloid beta distribution between brain and plasma

Broad-spectrum virus- and host-targeting peptide, inhibiting coronaviruses and other respiratory viruses

Agonist of dopamine receptor subtypes D1 and D2

Exceptionally Potent and Membrane-Embedded Inhibitor of Bilayer Lipid Peroxidation

Non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor

Novel allosteric inhibitor of E. coli Hsp70 (DnaK) and human Hsp70 proteins

First Inhibitor of PEX14-PEX5 Protein-Protein Interaction (PPI) with Trypanocidal Activity

Novel γ-secretase inhibitor

Dose dependent inhibitor of multiple fibrotic genes

Selective dopamine D3/D2 receptor antagonist

Novel potent and selective PDE8B/8A inhibitor

Irriversible inhibitor of kynurenine amino transferase II (KAT II)

Novel selective hTRPV4 Antagonist (hTRPV4 IC50 49nM; rTRPV4 IC50 1,150nM)

Novel potent TRPV4 antagonist (hTRPV4 IC50 4nM; rTRPV4 IC50 27nM)

Novel potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor

Potent and selective inhibitor of diacylglycerol acyltransferase 2 (DGAT2)

Novel non-brain-penetrant long-acting peptide oxytocin (OT) receptor agonist with increased selectivity for the OT receptor and significantly increased pharmacokinetic stability

Novel potent and selective inhibitor of MAP4K4

Novel tyrosine residues probe, rationally targeting active site

Novel potent and selective inhibitor of MAP4K4

PF-06835919, also known as MDK1846, is a potent ketohexokinase (KHK) inhibitor. PF-06835919 is reported in patent US 20170183328 A1, example 4. Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders.

Novel prdrug of PF-06843195, a potent PI3Kα-selective inhibitor

Novel SAM Competitive PRMT5 Inhibitor, Demonstrating Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Natural cyclic tetrapeptide HDAC Inhibitor through the inhibition of PfHDAC1 catalytic activity, potently inducing the synthesis of metallothionein

Potent, selective non-peptidic antagonist of the V1a receptor

Novel dual H3/4 histamine receptor antagonist

Highly selective, extremely potent Mps1 kinase inhibitor

Potent and selective 5-HT2C receptor agonist

Selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells

Novel, potent and specific inhibitor of sphingosine kinase-1 (SphK1)

Antimalarial, actively against Plasmodium liver stages

Potent, ATP-competitive, reversible inhibitor of FAK

Novel potent and selective inhibitor of the activation-loop mutant Kit phosphorylation and tumor growth

Novel Entry Inhibitor of both CCR5- and CXCR4-Tropic Strains of Human Immunodeficiency Virus Type 1 (HIV-1), Targeting a Novel Site on gp41

Highly selective, extremely potent Mps1 kinase inhibitor

Novel fluorophosphonate-based probe, specifically and covalently reacts with the tyrosine-111 residue of the Schistosoma japonicum GST (sjGST) tag, rapidly and site-selectively immobilizes sjGST fusion proteins

Novel dual CBP/p300 and BRD4 bromodomain inhibitor, downregulating IL-6, IL-ß and IFN-ß in macrophages

Negative control for PFI-7 (GLXC012596)

Novel selective inhibitor of both Plasmodium and Cryptosporidium lysyl-tRNA synthetase, clearing parasites from mouse models of malaria and cryptosporidiosis infection.

Novel inhibitor of Profilin1 (Pfn1), reducing the overall level of cellular filamentous (F)-actin, slowing EC migration and proliferation, and inhibiting the angiogenic ability of EC both in vitro and ex vivo

Novel inhibitor of Profilin1 (Pfn1), reducing the overall level of cellular filamentous (F)-actin, slowing EC migration and proliferation, and inhibiting the angiogenic ability of EC both in vitro and ex vivo

Water soluble derivative pro-drug of PG490 (triptolide)

Novel anti-HIF-1alpha agent

Potent and selective antagonist of the VIP1 receptor, inhibiting competitively effect of VIP on the VIP1 receptor mediated stimulation of adenylate cyclase activity with Ki values respectively of 15 ± 5 nM and 2 ± 1 nM for the rat and human VIP1 receptor

Novel allosteric PGAM1 inhibitor, showing efficacious in multiple preclinical models of pancreatic ductal adenocarcinoma (PDAC), especially with high PGAM1 expression

Novel allosteric PGAM1 inhibitor, showing efficacious in multiple preclinical models of pancreatic ductal adenocarcinoma (PDAC), especially with high PGAM1 expression

Novel potent matrix metalloproteinase (MMP) inhibitor, targeting MMPs 1, 3, 9, and 13 (24, 18, 1.9, and 1.3 nM, respectively)

Glycolytic enzyme phosphoglycerate mutase 1 (PGAM1) inhibitor

Inhibitor of both Bcr-Abl tyrosine kinase and Aurora kinases

Selective ATP competitive ALK inhibitor

Inhibitor of phagocytosis, interacting with and inhibiting the activating Fc receptors on macrophages, inhibiting downstream signaling pathways driving Fc-mediated phagocytosis

Natural nicotinic acetylcholine receptor agonist

Novel COX-2 inhibitor

Inhibitor of NMDA receptors, used as a veterinary anesthetic, and briefly as a general anesthetic for humans

Selective ligand of a specific G-quadruplex conformation, interacting with the quadruplex through extensive

Prodrug of phenoxodiol

Inhibitor of internalization of cell surface receptors and tyrosine phosphatases, with no effect on tyrosine kinase

Blocker of dsRNA-induced IRF3 nuclear translocation and homodimerization; Inhibitor of lipopolysaccharide-mediated Toll-like receptor-4 signaling; Inhibitor of human pancreatic cancer

Novel selective α-syn ligand, exhibited the promising binding characteristics for α-syn aggregates (Ki = 0.52 nM)

Novel neuropeptide, protecting human brain vascular endothelial cells against oxygen-glucose deprivation/reoxygenation (OGD/R)-induced inflammation and permeability, significantly ameliorating HFD-induced obesity and fatty liver, regulating pituitary gona

Novel GPR173 agonist, promoting osteoblastic differentiation of MC3T3-E1 cells. stimulating mRNAs encoding hypothalamo-pituitary-gonadal hormones

Natural anti-tumor agent, showing strong apoptotic anticancer effects against platinum-resistant solid cancers

Potent antagonist of (H1N1)pdm09 infection, markedly suppressing cytopathic effects and attenuating viral gene expression in (H1N1)pdm09-infected MDCK cells

Sulindac derivative with promising anticancer activities

Inducer of platelet aggregation, playing a role in cellular signal transduction and possibly in cell growth control and carcinogenesis

Novel photoswitchable BET bromodomain Degrader (PHOTAC)

Novel potent photoswitchable antagonist for a precise spatiotemporal control of β2-adrenoceptors

Novel photocontrol inhibitor of the voltage-gated proton channel Hv1

Functionalized photoswitchable cereblon ligand for Degraders

Novel photoswitchable sphingolipid probe, reversibly controlled S1P3-dependent pain hypersensitivity in mice and uniquely suited for the study of S1P biology in cultured cells and in vivo

Novel porphyrazine-based photodynamic anti-cancer agent, inducing immunogenic cell death

Novel porphyrazine-based photodynamic anti-cancer agent, inducing immunogenic cell death

Novel photoswitchable sphingolipid probe

Novel photoswitchable inhibitor of human dihydrofolate reductase

Natural flavonoidal alkaloid from the sea-grass Phyllosphadix iwatensis

Natural cytotoxic withanolide antitumor agent, inducing apoptosis by decreasing mitochondrial membrane potential and elevating the Bax/Bcl-2 protein expression ratio

Natural inhibitor of Wnt signaling, modulating β-catenin-dependent transcription

Platelet aggregation inhibitor

Platelet aggregation inhibitor

Novel Tau ligand, displaying high Tau binding, low MAO-A binding, high brain uptake, and fast and complete brain washout

Novel inhibitor of the PI3K/Akt/mTOR signaling pathways, activating P53 and inducing apoptosis

Novel Inhibitor of the PI3K-Akt Pathway, Inducing Autophagy of Female Germline Stem Cells

Highly potent ATP-competitive PI3Kdelta/Vps34 dual inhibitor

Novel potent PI3K inhibitor with a modified omipalisib structure

Novel PI3K inhibitor, synergizing with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.

Selective 5-HT4 receptor antagonist

Novel Subtype-Selective PPARbeta/delta Agonist

Potent and selective beta2-adrenoceptor agonist

Prodrug of GABA, used for treatment of neurogenic bladder in spinal and benign prostatic hyperplasia

Novel PI3K inhibitor, displaying potent preclinical activity against multiple myeloma

Natural activator of cryptic biosynthetic gene clusters (BGC), also acting as a potent inhibitor of monoamine oxidase B

Potent, highly selective, and orally bioavailable inhibitor of PIM-1 kinases

Novel potent PIM inhibitor

Antipsychotic agent

Inhibitor of PIP 4 Ks, efficiently killing transformed BJ cells, but not normal counterparts, displaying a strong selective lethality against Ras-activated or Ras-transformed cells

Partial agonist of benzodiazepine receptors

Antipsychotic prodrug, most notably used for schizophrenia

Antifungal antibiotic, showing inhibitory activity against fungi and yeasts, especially against Trichophyton

Novel potent in vitro and in vivo antifungal agent against azole-resistant Candida albicans

Natural nitric oxide (NO) production inhibitor

NSAID with better gastrointestinal (GI) tolerability

Inhibitor of the acetylcholinesterase activity from bovine erythrocytes and electric eel

Inhibitor of topoisomerase II, intercalating into DNA and inducing topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity

Potent ligand to target the Y220C pocket, stabilizing Y220C

Novel Protein Kinase C-iota (PKC-ι) Inhibitor, Binding Post-kinase Domain Residues

Novel selective inhibitor of protein kinase Cθ (PKCθ)

Novel highly potent and selective PKM2 inhibitor, blocking PKM2 mitochondrial translocation under nutritional stress and inhibits tumor growth in vivo

Novel potent and specific β5i inhibitor

Potent inhibitor of HipA toxin, inhibiting E. coli persistence

mRNA splicing inhibitor

Antilipidemic and antiplatelet agent

Novel Potent and Specific Inhibitor of Placental Alkaline Phosphatase (PLAP; IC 50 = 32 nM), Targeting Tumor of the Female Reproductive Tract

Novel Potent Activator of the Nonreceptor Protein Tyrosine Phosphatase Shp2

Gastroprotective agent, increasing the prostaglandin production in the gastric mucosa and accelerates ulcer healing

Broad spectrum aminoglycoside antibiotic typically used for moderate-to-severe urinary tract infections or pyelonephritis

Novel inhibitor of phospholipase C (PLC) isozyme

Novel enhancer of Reactive Oxygen Species (ROS), depleting glutathione levels in analogy to piperlongumine but with reduced cell death

Novel activator of AMPK, inducing apoptotic death in prostate cancer cells

Plk1 PBD-specific phosphopeptide inhibitor, effectively inhibiting mitotic progression and cell proliferation

Novel Inhibitor of the Polo-Box Domain of Polo-like Kinase 1 (Plk1 PBD)

Novel polo-like kinase 1 (PLK1) inhibitor

Slightly less potent inhibitor of FMS than PLX647 but has better aqueous solubility

Potent anticancer tetrahydroisoquinoline alkaloid, being able to form a covalent bond with the amino group of a guanine in selected triplets of DNA duplexes and eventually give rise to double-strand breaks

Novel inhibitor of β-catenin signaling, significantly reduced β-catenin activity in hepatoblastoma and several HCC cells

Novel potent irriversible dual inhibitor of tubulin and epidermal growth factor receptor (EGFR), inducing the apoptosis of A549 cells in a dose- and time-dependent manner, along with decrease in mitochondrial membrane potential (MMP), production of ROS an

Novel inhibitor of prenylated methylated protein methyl esterase (PMPMEase), a key enzyme in the reversible methylation/demethylation step in the protein prenylation pathway

Novel inhibitor of prenylated methylated protein methyl esterase (PMPMEase), a key enzyme in the reversible methylation/demethylation step in the protein prenylation pathway

Selective 5-HT1A serotonin receptor antagonist

Cell-permeable analog of pifithrin-α, potently blocking p53-mediated expression of p21/WAF1 and apoptosis

Novel G Protein-Biased Cannabinoid 1 (CB1) Receptor Agonist

Potent inhibitor of CDK2/cyclin A

Allosteric modulator of 5-HT(2C)R with no intrinsic agonist activity

The first small-molecule approach capable of detecting and controlling engineered cell-cell outputs

Novel microtubule destabilizing natural product from the Podophyllum species

Novel RNA polymerase I inhibitor, targeting ribosomal DNA G-quadruplexes, potently and selectively inhibiting cell growth by high-affinity binding to G4s in ribosomal DNA, impairing RNA polymerase I (Pol I) elongation, inducing a rapid inhibition of Pol I

Novel macrocycle antibiotic with selective and potent activity against P. aeruginosa

Novel modulator of protein-protein interactions of the mitotic polo-like kinases, targeting KRAS mutant xenografts, indicate avenues, acting synergistically with Crizotinib, an inhibitor of the c-MET receptor, against mutant KRAS-expressing cancer cells

Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis

Used for the transfection of a broad variety of cell lines; Antimicrobial; Novel binding agent of diffusive gradients in thin-films (DGT) technique (PEI-DGT)

Novel activator of Adenosine monophosphate (AMP)-activated protein kinase (AMPK)

Antibiotic as a last-line therapy to treat infections caused by these life-threatening 'superbugs'

Novel pan-inhibitor of KCa3.1/KCa2 channels

Potent Activator of Vγ9Vδ2 T-Lymphocytes; HMBPP ananlog prodrug

Hypobetalipoproteinemic and Lipid decreasing agent

Novel pan-human EGF receptor (HER) inhibitor

Novel iNOS homodimerization inhibitor

The first reported PPARα/δ dual antagonist

Novel dual PPARα/γ agonist, ameliorating insulin resistance and gluconeogenesis in vivo and vitro

Novel inhibitor of protein-protein interaction (PPI), blocking #212121; font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 14px; font-style: no

Novel insulin mimetic

Novel pan-RAS-effector PPI inhibitor

Novel PPK1 inhibitor, preventing UTI effectively through the disruption of the PPK1 function

Novel PPK1 inhibitor, preventing UTI effectively through the disruption of the PPK1 function

Potent and selective antagonist of melanocortin-4 receptor (MC4R)

Novel anti-influenza agent, interrupting the crucial RNP trafficking, resulting in influenza replication inhibition, preventing virus-induced cytopathic effects

Novel Modulator of Water-Heme Interactions in Low-Spin P450 Complexes of CYP2C9d and CYP125A1

Novel inhibitor of budding of mVP40 and eVP40 VLPs, blocking mVP40-795 Nedd4 protein-protein interaction.